Information Provided By:
Fly News Breaks for September 28, 2016
SRPT
Sep 28, 2016 | 08:46 EDT
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
News For SRPT From the Last 2 Days
There are no results for your query SRPT